Literature DB >> 19361747

Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes.

Koen van Besien1, Jeanette Carreras, Philip J Bierman, Brent R Logan, Arturo Molina, Roberta King, Gene Nelson, Joseph W Fay, Richard E Champlin, Hillard M Lazarus, Julie M Vose, Parameswaran N Hari.   

Abstract

We analyzed the outcomes of 283 patients receiving unrelated donor allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma (NHL) facilitated by the Center for International Blood and Marrow Transplant Research/National Marrow Donor Program (CIBMTR/NMDP) between 1991 and 2004. All patients received myeloablative conditioning regimens. The median follow-up of survivors is 5 years. Seventy-three (26%) patients are alive. The day 100 probability of death from all causes is estimated at 39%. The cumulative incidence of developing grade III-IV acute graft-versus-host disease (aGVHD) at day 100 is 25%. The estimated 5-year survival and failure free survival are 24% (95% confidence interval [CI]: 19-30) and 22% (95% CI: 17-28), respectively. Factors adversely associated with overall survival (OS) included increasing age, decreased performance status, and refractory disease. Follicular lymphoma (FL) and peripheral T cell lymphoma had improved survival compared to aggressive B cell lymphomas. Factors adversely associated with progression-free survival (PFS) included performance status, histology, and disease status at transplant. Long-term failure-free survival is possible following unrelated donor transplantation for NHL, although early mortality was high in this large cohort.

Entities:  

Mesh：

Year:  2009        PMID： 19361747      PMCID： PMC3120935          DOI： 10.1016/j.bbmt.2009.01.012

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


  43 in total

1.  A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma.

Authors:  John E Levine; Richard E Harris; Fausto R Loberiza; James O Armitage; Julie M Vose; Koen Van Besien; Hillard M Lazarus; Mary M Horowitz; Asad Bashey; Brian J Bolwell; Linda J Burns; Mitchell S Cairo; Richard E Champlin; Cesar O Freytes; John Gibson; Steve C Goldstein; Mary J Laughlin; John Lister; David I Marks; Richard T Maziarz; Alan M Miller; Gustavo A Milone; Santiago Pavlovsky; Amdrew L Pecora; J Douglas Rizzo; Gary Schiller; Harry C Schouten; Mei Jie Zhang
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

2.  Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes.

Authors:  Paolo Corradini; Marco Ladetto; Francesco Zallio; Monica Astolfi; Elena Rizzo; Selina Sametti; Alessandra Cuttica; Rosalba Rosato; Lucia Farina; Mario Boccadoro; Fabio Benedetti; Alessandro Pileri; Corrado Tarella
Journal:  J Clin Oncol       Date:  2004-04-15       Impact factor: 44.544

3.  Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome.

Authors:  Neal Flomenberg; Lee Ann Baxter-Lowe; Dennis Confer; Marcelo Fernandez-Vina; Alexandra Filipovich; Mary Horowitz; Carolyn Hurley; Craig Kollman; Claudio Anasetti; Harriet Noreen; Ann Begovich; William Hildebrand; Effie Petersdorf; Barbara Schmeckpeper; Michelle Setterholm; Elizabeth Trachtenberg; Thomas Williams; Edmond Yunis; Daniel Weisdorf
Journal:  Blood       Date:  2004-06-10       Impact factor: 22.113

4.  BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.

Authors:  Rowena D Faulkner; Charles Craddock; Jennifer L Byrne; Prem Mahendra; Andrew P Haynes; Hugh G Prentice; Michael Potter; Antonio Pagliuca; Aloysius Ho; Stephen Devereux; Grant McQuaker; Ghulam Mufti; John Liu Yin; Nigel H Russell
Journal:  Blood       Date:  2003-09-11       Impact factor: 22.113

5.  Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma.

Authors:  V Ratanatharathorn; J Uberti; C Karanes; E Abella; L G Lum; F Momin; G Cummings; L L Sensenbrenner
Journal:  Blood       Date:  1994-08-15       Impact factor: 22.113

6.  Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program.

Authors:  N A Kernan; G Bartsch; R C Ash; P G Beatty; R Champlin; A Filipovich; J Gajewski; J A Hansen; J Henslee-Downey; J McCullough
Journal:  N Engl J Med       Date:  1993-03-04       Impact factor: 91.245

7.  Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.

Authors:  Stephen P Robinson; Anthony H Goldstone; Stephen Mackinnon; Angelo Carella; Nigel Russell; Carmen Ruiz de Elvira; Goli Taghipour; Norbert Schmitz
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

8.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

9.  Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma.

Authors:  Issa F Khouri; Ming-S Lee; Rima M Saliba; Gu Jun; Luis Fayad; Anas Younes; Barbara Pro; Sandra Acholonu; Peter McLaughlin; Ruth L Katz; Richard E Champlin
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

10.  Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

Authors:  Paolo Corradini; Anna Dodero; Francesco Zallio; Daniele Caracciolo; Marco Casini; Marco Bregni; Franco Narni; Francesca Patriarca; Mario Boccadoro; Fabio Benedetti; A Rambaldi; Alessandro M Gianni; Corrado Tarella
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544
View more
  16 in total

1.  Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.

Authors:  Anna Sureda; Mei-Jie Zhang; Peter Dreger; Jeanette Carreras; Timothy Fenske; Herve Finel; Harry Schouten; Silvia Montoto; Stephen Robinson; Sonali M Smith; Ariane Boumedil; Mehdi Hamadani; Marcelo C Pasquini
Journal:  Cancer       Date:  2018-02-09       Impact factor: 6.860

2.  Long-term follow-up of patients with relapsed or refractory non-Hodgkin's lymphoma receiving allogeneic stem cell transplantation.

Authors:  C S Link; F Mies; J Scheele; M Kramer; J Schetelig; R Ordemann; M Hänel; M Bornhäuser; G Ehninger; F Kroschinsky
Journal:  Bone Marrow Transplant       Date:  2016-06-13       Impact factor: 5.483

3.  Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party.

Authors:  K Horstmann; A Boumendil; J Finke; H Finel; E Kanfer; G Milone; N Russell; A Bacigalupo; Y Chalandon; J L Diez-Martin; N Ifrah; M Jurado Chacon; P Dreger
Journal:  Bone Marrow Transplant       Date:  2015-03-09       Impact factor: 5.483

4.  Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma.

Authors:  Frank Heinzelmann; Wolfgang Bethge; Dietrich Wilhelm Beelen; Matthias Stelljes; Peter Dreger; Marianne Engelhard; Jürgen Finke; Nikolaus Kröger; Ernst Holler; Martin Bornhäuser; Annerose Müller; Imme Haubitz; Hellmut Ottinger
Journal:  J Cancer Res Clin Oncol       Date:  2018-04-05       Impact factor: 4.553

Review 5.  Stem cell transplantation for indolent lymphoma: a reappraisal.

Authors:  Koen van Besien
Journal:  Blood Rev       Date:  2011-09       Impact factor: 8.250

Review 6.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.

Authors:  Steven Z Pavletic; Shaji Kumar; Mohamad Mohty; Marcos de Lima; James M Foran; Marcelo Pasquini; Mei-Jie Zhang; Sergio Giralt; Michael R Bishop; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-04-24       Impact factor: 5.742

Review 7.  Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.

Authors:  A Sureda; P Bader; S Cesaro; P Dreger; R F Duarte; C Dufour; J H F Falkenburg; D Farge-Bancel; A Gennery; N Kröger; F Lanza; J C Marsh; A Nagler; C Peters; A Velardi; M Mohty; A Madrigal
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

8.  Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma.

Authors:  I Avivi; C Canals; J-P Vernant; G Wulf; A Nagler; O Hermine; E Petersen; I Yakoub-Agha; C Craddock; A Schattenberg; D Niederwieser; K Thomson; D Blaise; M Attal; M Pfreundschuh; J Passweg; N Russell; P Dreger; A Sureda
Journal:  Bone Marrow Transplant       Date:  2014-02-10       Impact factor: 5.483

9.  Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT.

Authors:  M-A Perales; R Jenq; J D Goldberg; A S Wilton; S S E Lee; H R Castro-Malaspina; K Hsu; E B Papadopoulos; M R M van den Brink; F Boulad; N A Kernan; T N Small; S Wolden; N H Collins; M Chiu; G Heller; R J O'Reilly; T Kewalramani; J W Young; A A Jakubowski
Journal:  Bone Marrow Transplant       Date:  2010-01-11       Impact factor: 5.483

10.  Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation.

Authors:  Veronika Bachanova; Daniel J Weisdorf; Tao Wang; Steven G E Marsh; Elizabeth Trachtenberg; Michael D Haagenson; Stephen R Spellman; Martha Ladner; Lisbeth A Guethlein; Peter Parham; Jeffrey S Miller; Sarah A Cooley
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-21       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.